» Articles » PMID: 28006001

Detectable Viral Load in Late Pregnancy Among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study

Overview
Journal PLoS One
Date 2016 Dec 23
PMID 28006001
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

There are limited viral load (VL) data available from programs implementing "Option B+," lifelong antiretroviral treatment (ART) to all HIV-positive pregnant and postpartum women, in resource-limited settings. Extent of viral suppression from a prevention of mother-to-child transmission of HIV program in Rwanda was assessed among women enrolled in the Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV (Kabeho) Study. ARV drug resistance testing was conducted on women with VL>2000 copies/ml. In April 2013-January 2014, 608 pregnant or early postpartum HIV-positive women were enrolled in 14 facilities. Factors associated with detectable enrollment VL (>20 copies/ml) were examined using generalized estimating equations. The most common antiretroviral regimen (56.7%, 344/607) was tenofovir/lamivudine/efavirenz. Median ART duration was 13.5 months (IQR 3.0-48.8); 76.1% of women were on ART at first antenatal visit. Half of women (315/603) had undetectable RNA-PCR VL and 84.6% (510) had <1,000 copies/ml. Detectable VL increased among those on ART > 36 months compared to those on ART 4-36 months (72/191, 37.7% versus 56/187, 29.9%), though the difference was not significant. The odds of having detectable enrollment VL decreased significantly as duration on ART at enrollment increased (AOR = 0.99, 95% CI: 0.9857, 0.9998, p = 0.043). There was a higher likelihood of detectable VL for women with lower gravidity (AOR = 0.90, 95% CI: 0.84, 0.97, p = 0.0039), no education (AOR = 2.25, (95% CI: 1.37, 3.70, p = 0.0004), nondisclosure to partner (AOR = 1.97, 95% CI: 1.21, 3.21, p = 0.0063) and side effects (AOR = 2.63, 95% CI: 1.72, 4.03, p<0.0001). ARV drug resistance mutations were detected in all of the eleven women on ART > 36 months with genotyping available. Most women were receiving ART at first antenatal visit, with relatively high viral suppression rates. Shorter ART duration was associated with higher VL, with a concerning increasing trend for higher viremia and drug resistance among women on ART for >3 years.

Citing Articles

Role of Dolutegravir-based antiretroviral treatment in achieving an undetectable HIV-1 viral load among women attending prevention of mother-to-child transmission clinics in Addis Ababa, Ethiopia.

Woldesemayat B, Getaneh Y, Adane S, Yizengaw A, Yilma A, Haile S SAGE Open Med. 2025; 13:20503121251320460.

PMID: 39949329 PMC: 11822805. DOI: 10.1177/20503121251320460.


Virological outcomes of antiretroviral therapy and its determinants among HIV patients in Ethiopia: Implications for achieving the 95-95-95 target.

Kitaw T, Haile R PLoS One. 2025; 20(1):e0313481.

PMID: 39746073 PMC: 11694995. DOI: 10.1371/journal.pone.0313481.


The Impact of a Couple-Based Intervention on One-Year Viral Suppression Among Pregnant Women Living With HIV and Their Male Partners in Malawi: A Randomized Controlled Trial.

Rosenberg N, Graybill L, Mtande T, McGrath N, Maman S, Nthani T J Acquir Immune Defic Syndr. 2024; 98(4):386-394.

PMID: 39710869 PMC: 11841716. DOI: 10.1097/QAI.0000000000003583.


Assessment of the effect of pre-conception care on preventing mother-to-child transmission of HIV in Nyeri County.

Ndapatani L, Mapesa J, Muchina E Pan Afr Med J. 2024; 47:144.

PMID: 38933429 PMC: 11204976. DOI: 10.11604/pamj.2024.47.144.37196.


Association of comprehensiveness of antiretroviral care and detectable HIV viral load suppression among pregnant and postpartum women in the Democratic Republic of the Congo: a cross-sectional study.

Boisson-Walsh A, Ravelomanana N, Tabala M, Malongo F, Kawende B, Babakazo P Front Glob Womens Health. 2024; 5:1308019.

PMID: 38903153 PMC: 11188341. DOI: 10.3389/fgwh.2024.1308019.


References
1.
Stadeli K, Richman D . Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2012; 18(1):115-23. PMC: 4295493. DOI: 10.3851/IMP2437. View

2.
Denoeud-Ndam L, Fourcade C, Ogouyemi-Hounto A, Azon-Kouanou A, dAlmeida M, Azondekon A . Predictive factors of plasma HIV suppression during pregnancy: a prospective cohort study in Benin. PLoS One. 2013; 8(3):e59446. PMC: 3598754. DOI: 10.1371/journal.pone.0059446. View

3.
Townsend C, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H . Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014; 28(7):1049-57. DOI: 10.1097/QAD.0000000000000212. View

4.
Nielsen-Saines K, Watts D, Veloso V, Bryson Y, Joao E, Pilotto J . Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012; 366(25):2368-79. PMC: 3590113. DOI: 10.1056/NEJMoa1108275. View

5.
Ngarina M, Kilewo C, Karlsson K, Aboud S, Karlsson A, Marrone G . Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect Dis. 2015; 15:175. PMC: 4392730. DOI: 10.1186/s12879-015-0914-z. View